Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell E Ware

Showing results (211-220 of 267) with videos related to

Pageof 27
Sort By:
Blood Advances|April 9, 2026
Growth and puberty in African children with sickle cell anemia treated with hydroxyureaPhilippe Backeljauw, George Tomlinson, Luke R Smart, et al.
American Journal of Hematology|February 9, 2024
Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trialAlexandra Power-Hays, George A Tomlinson, Leon Tshilolo, et al.
The New England Journal of Medicine|May 27, 2026
Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell AnemiaRussell E Ware, Robert O Opoka, Teresa Latham, et al.
Blood Vessels, Thrombosis & Hemostasis|August 6, 2025
Angiopoietin-2 is associated with sickle cell complications, including stroke risk, and decreases with hydroxyurea therapyThomas F Siegert, Robert O Opoka, Maria Nakafeero, et al.
Pediatric Blood & Cancer|August 10, 2011
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overloadRussell E Ware, William H Schultz, Nancy Yovetich, et al.
British Journal of Haematology|July 6, 2021
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemiaCharles T Quinn, Omar Niss, Min Dong, et al.
American Journal of Hematology|November 29, 2011
Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke preventionJanet L Kwiatkowski, Alan R Cohen, Julian Garro, et al.
British Journal of Clinical Pharmacology|April 13, 2025
The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trialAlexandra Power-Hays, Ruth Namazzi, Min Dong, et al.
American Journal of Hematology|May 31, 2020
Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell diseaseAlex George, Bogdan Dinu, Norma Estrada, et al.
Blood|November 14, 2022
Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan AfricaPeter Olupot-Olupot, George Tomlinson, Thomas N Williams, et al.
Pageof 27

Showing results (211-220 of 267) with videos related to

Sort By:
Pageof 27
Blood Advances|April 9, 2026
Growth and puberty in African children with sickle cell anemia treated with hydroxyureaPhilippe Backeljauw, George Tomlinson, Luke R Smart, et al.
American Journal of Hematology|February 9, 2024
Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trialAlexandra Power-Hays, George A Tomlinson, Leon Tshilolo, et al.
The New England Journal of Medicine|May 27, 2026
Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell AnemiaRussell E Ware, Robert O Opoka, Teresa Latham, et al.
Blood Vessels, Thrombosis & Hemostasis|August 6, 2025
Angiopoietin-2 is associated with sickle cell complications, including stroke risk, and decreases with hydroxyurea therapyThomas F Siegert, Robert O Opoka, Maria Nakafeero, et al.
Pediatric Blood & Cancer|August 10, 2011
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overloadRussell E Ware, William H Schultz, Nancy Yovetich, et al.
British Journal of Haematology|July 6, 2021
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemiaCharles T Quinn, Omar Niss, Min Dong, et al.
American Journal of Hematology|November 29, 2011
Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke preventionJanet L Kwiatkowski, Alan R Cohen, Julian Garro, et al.
British Journal of Clinical Pharmacology|April 13, 2025
The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trialAlexandra Power-Hays, Ruth Namazzi, Min Dong, et al.
American Journal of Hematology|May 31, 2020
Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell diseaseAlex George, Bogdan Dinu, Norma Estrada, et al.
Blood|November 14, 2022
Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan AfricaPeter Olupot-Olupot, George Tomlinson, Thomas N Williams, et al.
Pageof 27